1198765-14-8

Basic information

• Product Name: N-(3-bromo-2-(((tert-butyldimethylsilyl)oxy)methyl)phenyl)-4-cyclopropyl-2-methylbenzamide
• Synonyms: N-(3-bromo-2-(((tert-butyldimethylsilyl)oxy)methyl)phenyl)-4-cyclopropyl-2-methylbenzamide
• CAS NO: 1198765-14-8
• Molecular Weight: 474.513
• Mol File: 1198765-14-8.mol

Chemical Properties

• CAS DataBase Reference: N-(3-bromo-2-(((tert-butyldimethylsilyl)oxy)methyl)phenyl)-4-cyclopropyl-2-methylbenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-bromo-2-(((tert-butyldimethylsilyl)oxy)methyl)phenyl)-4-cyclopropyl-2-methylbenzamide(1198765-14-8)
• EPA Substance Registry System: N-(3-bromo-2-(((tert-butyldimethylsilyl)oxy)methyl)phenyl)-4-cyclopropyl-2-methylbenzamide(1198765-14-8)

Safety Data

• Hazardous Substances Data: 1198765-14-8(Hazardous Substances Data)

Upstream product

• 861106-91-4 (2-bromo-6-nitro-phenyl)-methanol 
• 1147531-02-9 ((2-bromo-6-nitrobenzyl)oxy)(tert-butyl)dimethylsilane 
• 909698-10-8 4-cyclopropyl-2-methylbenzoic acid 
• 1147531-04-1 3-bromo-2-[[tert-butyl(dimethyl)silyl]oxymethyl] aniline 
• 68837-59-2 4-bromo-2-methylbenzoic acid 
• 99548-55-7 4-bromo-2-methyl-benzoic acid methyl ester 
• 909698-09-5 methyl 4-cyclopropyl-2-methylbenzoate 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 861106-90-3 2-bromo-6-nitrobenzyl acetate 
• 58579-54-7 3-bromo-2-(bromomethyl)-1-nitrobenzene 
• 55289-35-5 2-bromo-6-nitrotoluene 
• 1198765-13-7 4-cyclopropyl-2-methylbenzoyl chloride 

Downstream Products

• 1198765-24-0 2-[3-Bromo-2-(tert-butyl-dimethyl-silanyloxymethyl)-phenyl]-3-tert-butoxymethyl-6-cyclopropyl-2H-isoquinolin-1-one 
• 1198765-16-0 2-[3-bromo-2-(tert-butyldimethylsilanyloxymethyl)phenyl]-6-cyclopropyl-2H-isoquinolin-1-one 
• 1198765-21-7 2-[3-Bromo-2-(tert-butyl-dimethyl-silanyloxymethyl)-phenyl]-6-cyclopropyl-3-methyl-2H-isoquinolin-1-one 
• 1198765-15-9 2-(3-bromo-2-{[(tert-butyldimethylsilyl)oxy]methyl}phenyl)-6-cyclopropyl-3-hydroxy-3,4-dihydro-2H-isoquinolin-1-one 

Relevant articles and documents

ISOQUINOLONES AS BTK INHIBITORS

The present invention encompasses compounds of the formula (I) wherein the groups R1, R2, R3, R4 and R5 are defined herein, which are suitable for the treatment of diseases related to Bruton's tyrosine kinase (BTK), and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.

Structure-based drug design of RN486, a potent and selective Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis

Structure-based drug design was used to guide the optimization of a series of selective BTK inhibitors as potential treatments for Rheumatoid arthritis. Highlights include the introduction of a benzyl alcohol group and a fluorine substitution, each of which resulted in over 10-fold increase in activity. Concurrent optimization of drug-like properties led to compound 1 (RN486) (J. Pharmacol. Exp. Ther. 2012, 341, 90), which was selected for advanced preclinical characterization based on its favorable properties.

SUBSTITUTED 1H-PYRROLOPYRIDINONE DERIVATIVES AS KINASE INHIBITORS

The present invention provides novel substituted 1H-Pyrrolopyridinone derivatives of formula (1) as protein kinase inhibitors, in which R1, R2, R3, R4, R5, R6 and 'p' have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting kinase enzyme, more particularly BTK enzyme. The present invention also provides methods for synthesizing and administering the kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

Inhibitors of Bruton's Tyrosine Kinase

This application discloses 5-phenyl-1H-pyridin-2-one, 6-phenyl-2H-pyridazin-3-one, and 5-Phenyl-1H-pyrazin-2-one derivatives according to generic Formulae I-III: wherein, variables Q, R, X, X′, Y1, Y2, Y2′, Y3, Y4, Y5, m, and n are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formulae I-III and at least one carrier, diluent or excipient.